Literature DB >> 11949499

[From the chemical product to the authorization of drug marketing].

Charles Caulin1.   

Abstract

A great number of highly qualified specialists are involved in the drug development process, mainly chemists, galenic and pharmacokinetic experts, pharmacologists and toxicologists. The 7 to 15 years development process implies preclinical studies in thousands of animals as well as clinical studies in about 3,000 patients. Various mandatory studies, regulatory requirements as well as a drug assessment process lead to the possible marketing authorization approval. The drug assessment process usually leads to a sound assessment of pharmaceutical quality of clinical benefit in each indication proposed; yet, occasionally, the assessment of safety is incomplete. Performing phase IV studies, collecting pharmacovigilance data is a requirement in the future. The prescriber of a newly approved drug must remain highly watchful.

Entities:  

Mesh:

Year:  2002        PMID: 11949499

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  1 in total

1.  Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom.

Authors:  Anna Raber; Joan Heras; Joan Costa; Josep Fortea; Albert Cobos
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.